SCHEMBL3539433

SCHEMBL3539433

O=C(c1csc(-c2ccsc2)n1)N1CCCC2CCCC=C21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.40
NTMT1 Q9BV86 1/20 0.36
ACKR3 P25106 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
HTR2C P28335 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
CHRNA7 P36544 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
CLK1 P49759 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM5A P29375 1/20 0.33
HTR6 P50406 1/20 0.32
PIN1 Q13526 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535648 0.87 ACKR3 (0.47) CHEK1ACKR3CNR1CNR2HTR3E
SCHEMBL3537642 0.86 ACKR3 (0.38) NTMT1ACKR3CNR1CNR2HTR2C
SCHEMBL3545134 0.85 ACKR3 (0.46) CHEK1ACKR3CNR1CNR2HTR3E
SCHEMBL3542690 0.85 RAB9A (0.45) HTR2CKDM4EALDH1A1KMT2A
SCHEMBL3539439 0.85 ALDH1A1 (0.48) NTMT1ACKR3CNR1CNR2KDM4E
SCHEMBL4983913 0.84 ACKR3 (0.45) ACKR3CNR1CNR2ALDH1A1HTR3E
SCHEMBL3537684 0.84 KDM4E (0.44) CHEK1NTMT1KDM4EALDH1A1KMT2A
SCHEMBL3540819 0.83 ACKR3 (0.41) ACKR3CNR1CNR2HTR2CKDM4E
SCHEMBL3538570 0.83 HDAC6 (0.48) CHEK1
SCHEMBL5661785 0.83 ACKR3 (0.38) NTMT1ACKR3CNR1CNR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 CHEK1 2565/4885NTMT1 2845/4885ACKR3 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.